Home/Pipeline/Ilumya (tildrakizumab)

Ilumya (tildrakizumab)

Psoriasis

ApprovedCommercial

Key Facts

Indication

Psoriasis

Phase

Approved

Status

Commercial

Company

Sun Pharmaceutical

About Sun Pharmaceutical

Founded in 1983, Sun Pharma has grown through strategic acquisitions and organic expansion to become a $4.5 billion revenue pharmaceutical giant. The company operates manufacturing facilities across India, USA, Canada, Brazil, Mexico and other countries, serving both developed and emerging markets. Sun Pharma is particularly known for its dermatology franchise and complex generics portfolio, with a growing presence in specialty therapeutics and biosimilars.

View full company profile

Therapeutic Areas

Dermatology Ophthalmology Cardiology Psychiatry Neurology Gastroenterology Oncology Generic Medicines

Other Psoriasis Drugs

Drug	Company	Phase	Status
Taltz (ixekizumab)	Eli Lilly	Approved	Commercial
SCD-044	Sun Pharmaceutical	Phase 2	Active
Itolizumab	Biocon	Approved	Commercial
SCD-105	SPARC	Phase 2	Completed
IMP731	Immutep	Phase 1/Ib	Completed
CYPS317	FibroBiologics	Discovery	Active